Neuroimaging features of CSF α‐synuclein seed amplification assay positivity in elderly individuals in AD continuum
Duygu Tosun, Susan M Landau, Michael S W Weiner, Cornelis Blauwendraat, Alzheimer's Disease Neuroimaging Initiative · 2025
Read Neuroimaging features of CSF α‐synuclein seed amplification assay positivity in elderly individuals in AD continuum by Duygu Tosun, Susan M Landau, Michael S W Weiner, Cornelis Blauwendraat, Alzheimer's Disease Neuroimaging Initiative (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716179.txt.
Description
Duygu Tosun and co-authors ask what a spinal fluid test for Lewy body pathology means for the brain scans of Alzheimer's patients, in this 2025 study. The test detects seeds of alpha-synuclein, the protein that clumps in Lewy body disease, which often coexists with Alzheimer's. The team, working with the Alzheimer's Disease Neuroimaging Initiative, studied amyloid-positive people with cognitive impairment.
Participants had spinal fluid tested and, within a year, brain scans measuring amyloid, tau, and shrinkage. Those testing positive showed more amyloid and tau signal in several temporal and frontal regions, and more shrinkage in others, even after adjusting for age, sex, and genetic risk. Follow-up scans were fewer, but positive patients lost tissue faster in middle frontal and parietal areas. The authors read the pattern as a sign that mixed pathology shapes how Alzheimer's unfolds.
Catalog record
| CREATOR | Duygu Tosun, Susan M Landau, Michael S W Weiner, Cornelis Blauwendraat, Alzheimer's Disease Neuroimaging Initiative |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |